Document is current
Any future updates will be listed below
-
Authors
Kürten, Cornelius H. L. https://orcid.org/0000-0002-2720-0075
Kulkarni, Aditi
Cillo, Anthony R. https://orcid.org/0000-0002-3213-3129
Santos, Patricia M.
Roble, Anna K. https://orcid.org/0000-0002-9435-4939
Onkar, Sayali
Reeder, Carly
Lang, Stephan
Chen, Xueer
Duvvuri, Umamaheswar
Kim, Seungwon
Liu, Angen
Tabib, Tracy
Lafyatis, Robert
Feng, Jian
Gao, Shou-Jiang https://orcid.org/0000-0001-6194-1742
Bruno, Tullia C. https://orcid.org/0000-0002-6433-0207
Vignali, Dario A. A.
Lu, Xinghua https://orcid.org/0000-0002-8599-2269
Bao, Riyue
Vujanovic, Lazar https://orcid.org/0000-0003-1729-8619
Ferris, Robert L.
-
Funding
Funding for this research was provided by:
Programm zur internen Forschungsforderung Essen (IFORES) UMEA Junior Clinician Scientist
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA047904, P50 CA097190, R01 CA206517)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 26 April 2020
Accepted: 16 November 2021
First Online: 17 December 2021
Competing interests
: R.L.F: Aduro Biotech, Inc; EMD Serono; MacroGenics, Inc.; Numab Therapeutics AG; Pfizer; Sanofi Tesaro; Zymeworks, Inc (honoraria); Astra-Zeneca/MedImmune (clinical trial, research funding); Bristol-Myers Squibb (honoraria, clinical trial, research funding); Merck (honoraria, clinical trial); Novasenta (honoraria, stock, research funding); (research funding). D.A.A.V.: Stock: Novasenta, Tizona, Trishula, Oncorus, Werewolf, Apeximmune; Consultancy: Tizona, Werewolf, F-Star, Astellas, BMS, MPM, Incyte, Bicara, Apeximmune, G1 Therapeutics, Innovent Bio, Kronos Bio; Grants: BMS, Astellas, Novasenta; Patents licensed and Royalties: Astellas, BMS, Novasenta. The remaining authors declare no competing interests.
